Skip to main content

Voyager Therapeutics, Inc.

corporate_fare Company Profile

Voyager Therapeutics, Inc.

VYGR·NASDAQ·Life Sciences·CIK 0001640266

We are a biotechnology company focused on using human genetics to treat neurological diseases. Our product pipeline includes programs for Alzheimer's disease (AD), Friedreich's ataxia (FA), Parkinson's disease (PD), and other central nervous system (CNS) diseases. Many programs originate from our TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus (AAV) capsid discovery platform. This platform generates novel capsids, called TRACER Capsids, and identifies associated receptors to potentially enable high brain penetration for genetic medicines after intravenous (IV) dosing. Some programs are wholly-owned, while others are developed with licensees and collaborators such as Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc.; and Transition Bio, Inc. We are developing our own pipeline of drug candidates for neurological diseases, with a focus on AD. Our wholly-owned prioritized pipeline includes two tau targeting programs: VY1706, a tau silencing gene therapy for AD, and VY7523, an anti-tau antibody for AD. VY1706 is a gene therapy that uses an intravenously delivered TRACER Capsid containing a vectorized small interfering RNA targeting tau mRNA. In a non-human primate (NHP) study, a single 1.3E13 vector genomes per kilogram (vg/kg) IV dose of VY1706 reduced tau mRNA levels by 50% to 73% across the cerebral cortex, including brain areas where tau accumulates in AD.

Voyager Therapeutics, Inc. (NASDAQ:VYGR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for VYGR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for VYGR spans 10-Q, 8-K, DEF 14A, PRE 14A.

Recent high-impact activity:

  • Voyager Q3 Loss Narrows to $24.7M; $132.1M Cash Funds Operations Into Q2 2028
  • Voyager Promotes Robin Swartz to President, Taps Her as Next CEO
  • Voyager Names Robin Swartz President; CEO Succession Set for Q1 2027
  • Voyager's VY1706 Delivers 75% Tau Reduction and Clean Safety in Six-Month Primate Study
  • Voyager's Alzheimer's Gene Therapy Shows 75% Tau Reduction, Trial Start H2 2026

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$40.37M
Net Income
-$119.72M
Diluted EPS
-$2.04
Op. Cash Flow
-$132.47M
Free Cash Flow
-$135.06M
Operating Income
-$131.84M
Cash & Equivalents
$65.3M
Debt / Equity
0.00×
Net Margin
-296.5%
Shares Outstanding
59.05M sh
Source: 10-K · filed 2026-03-09 · accession 0001104659-26-025197

Short Interest & Short Volume

4.10 days to cover

FINRA reported short interest of 4,377,124 shares in VYGR as of the October 30, 2026 settlement, a 20.3% increase from the prior period — about 4.1 days to cover at its recent average daily volume. On November 19, 2026, 47.2% of VYGR volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)4,377,124 shares as of October 30, 2026
Change vs prior period▲ 20.3%
Days to cover4.10 at avg daily volume of 1,067,399
Daily short volume (FINRA facilities)47.2% of 281,654 shares on November 19, 2026
5-day average short volume62.5%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for VYGR, detected from its recent SEC filings · based on capital-structure filings through 2026-06-10.

Authorized Shares Doubled · Enables Future Capital Flexibility

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with V →
$1.52 -5.59% today
52-week range · as of 2026-11-05 $1.52 – $5.48
Market cap
$95.21M
Volume
493.1K (0.5× avg)
3-mo avg 993K
Live data · 2026-11-20 20:42 UTC · Market open

show_chartPrice Chart

Loading chart...

feed VYGR - Latest Insights

VYGR
Nov 05, 2026, 4:01 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.69
Real-time Price: $1.52 info
Change: -$0.170 (-10%) info
Market Cap: $95.211M info
VYGR
Oct 21, 2026, 8:09 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $2.15
Real-time Price: $1.52 info
Change: -$0.630 (-29%) info
Market Cap: $95.211M info
VYGR
Oct 21, 2026, 8:07 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.15
Real-time Price: $1.52 info
Change: -$0.630 (-29%) info
Market Cap: $95.211M info
VYGR
Jul 13, 2026, 8:44 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.54
Real-time Price: $1.52 info
Change: -$2.02 (-57%) info
Market Cap: $95.211M info
VYGR
Jul 13, 2026, 8:01 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.45
Real-time Price: $1.52 info
Change: -$1.93 (-56%) info
Market Cap: $95.211M info
VYGR
Jun 10, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.32
Real-time Price: $1.52 info
Change: -$1.80 (-54%) info
Market Cap: $95.211M info
VYGR
Jun 01, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.88
Real-time Price: $1.52 info
Change: -$2.36 (-61%) info
Market Cap: $95.211M info
VYGR
Jun 01, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $3.98
Real-time Price: $1.52 info
Change: -$2.46 (-62%) info
Market Cap: $95.211M info
VYGR
May 13, 2026, 6:01 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $4.32
Real-time Price: $1.52 info
Change: -$2.80 (-65%) info
Market Cap: $95.211M info
VYGR
May 07, 2026, 4:04 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.96
Real-time Price: $1.52 info
Change: -$2.44 (-62%) info
Market Cap: $95.211M info
VYGR
Apr 28, 2026, 4:00 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $3.77
Real-time Price: $1.52 info
Change: -$2.25 (-60%) info
Market Cap: $95.211M info
VYGR
Apr 21, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.12
Real-time Price: $1.52 info
Change: -$2.60 (-63%) info
Market Cap: $95.211M info
VYGR
Apr 10, 2026, 4:22 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $3.76
Real-time Price: $1.52 info
Change: -$2.24 (-60%) info
Market Cap: $95.211M info
VYGR
Mar 09, 2026, 4:02 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $4.11
Real-time Price: $1.52 info
Change: -$2.59 (-63%) info
Market Cap: $95.211M info
VYGR
Mar 09, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.98
Real-time Price: $1.52 info
Change: -$2.46 (-62%) info
Market Cap: $95.211M info
VYGR
Feb 12, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.65
Real-time Price: $1.52 info
Change: -$2.13 (-58%) info
Market Cap: $95.211M info
VYGR
Jan 08, 2026, 8:16 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.05
Real-time Price: $1.52 info
Change: -$2.53 (-62%) info
Market Cap: $95.211M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets